首页> 外文期刊>Basic & clinical pharmacology & toxicology. >TDM11 FOOD INTERACTION BIOAVAILABILITY STUDY OF A TORASEMIDE NEW FORMULATION (10 MG PROLONGED RELEASE) AFTER A HIGH FAT CONTENT MEAL
【24h】

TDM11 FOOD INTERACTION BIOAVAILABILITY STUDY OF A TORASEMIDE NEW FORMULATION (10 MG PROLONGED RELEASE) AFTER A HIGH FAT CONTENT MEAL

机译:高脂肪餐后,甲苯磺酰胺新配方(10毫克增强释放)的TDM11食品相互作用生物有效性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: To evaluate the effect of food interaction in the bioavail-ability of a new prolonged release formulation of Torasemide (Tora-semi de-PR).Setting: Intra-hospital Phase-I Unit.Methods: The food interaction effect on bioavailability of a new prolonged release formulation of Torasemide was evaluated in a single-dose, randomized, 3-way cross-over, clinical trial. The study included 18 healthy volunteers who received one administration of 10 mg Torasemide immediate release (IR) in fasting conditions (IR-F), one administration of 10 mg Torasemide-PR in fasting conditions (PR-F) and one administration of 10 mg Torasemide-PR after a high fat content meal (PR-M). Each administration was separated by a minimum of 7 days wash-out period. Blood samples were obtained for determination of pharmacokinetic parameters. Safety and tolerability were also assessed.Results: The main results of the analysis of the plasmatic pharmacokinetic parameters are the following. 1) mean PR-F/mean 1R-F (90% C.I.):LnAUC_(0-t)=101.18 (92.64-110.50); Ln AUC0_ = 101.20 (92.66-110.52); Ln C_(max)=67.48 (55.34-82.29) . 2) mean PR-M/ mean PR-F (90% C.I.): Ln AUC_(0-t)=89.04 (81.52-97.24); Ln AUC0 ,,=89.06 (81.55-97.27); Ln C_(max)=79.07 (64.84-96.43). No significant adverse events were reported.Conclusions: When administered in fasting conditions, both Torasemide formulations showed similar systemic exposures represented by AUC values within the bioequivalence 90% C.I. acceptance criteria (80-125%). Torasemide PR C_(max)values were statistically significant lower than Torasemide IR C_(max)values. When administered after a high fat content meal, Torasemide-PR shows a reduction in C_(max)in relation to its administration in fasting conditions; although, the systemic exposure (AUCs) remains within the bioequivalence 90% C.I. acceptance criteria (80-125%). Both formulations where well tolerated and presented a good safety profile.
机译:目的:评价食物相互作用对新的Torasemide缓释制剂(Tora-semi de-PR)的生物利用度的影响设置:医院内I期单元方法:食物相互作用对香豆素生物利用度的影响在单剂量,随机,三向交叉,临床试验中评估了新的Torasemide缓释制剂。该研究包括18名健康志愿者,他们在禁食条件下(IR-F)接受10毫克Torasemide立即释放(IR)的一次给药,在禁食条件下(PR-F)接受10毫克Torasemide-PR的一次给药,以及10毫克给药高脂肪餐(PR-M)后使用Torasemide-PR。每次给药至少间隔7天。获得血样用于确定药代动力学参数。结果:血浆药代动力学参数分析的主要结果如下。 1)平均PR-F /平均1R-F(90%C.I.):LnAUC_(0-t)= 101.18(92.64-110.50); Ln AUC0_ = 101.20(92.66-110.52); Ln C_(max)= 67.48(55.34-82.29)。 2)平均PR-M /平均PR-F(90%C.I.):Ln AUC_(0-t)= 89.04(81.52-97.24); Ln AUC 0,= 89.06(81.55-97.27); Ln C_(max)= 79.07(64.84-96.43)。结论:在空腹条件下给药时,两种Torasemide制剂均表现出相似的全身暴露,其生物等效性为90%C.I.。验收标准(80-125%)。 Torasemide的PR C_(max)值在统计学上显着低于Torasemide的IR C_(max)值。在高脂肪含量餐后服用时,Torasemide-PR与空腹情况下的C_(max)相比降低。虽然,全身暴露(AUC)仍在生物等效性90%C.I.以内。验收标准(80-125%)。两种配方均具有良好的耐受性,并具有良好的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号